Longevity & AgingPress Release

Semaglutide Cuts BMI in Children With Obesity as Young as 6 in Phase III Trial

The STEP Young trial found weekly semaglutide lowered BMI by 13.5% at 68 weeks in children ages 6 to 11, with 38% dropping below the obesity threshold.

Tuesday, November 17, 2026 0 views
Published in MedPage Today
Article visualization: Semaglutide Cuts BMI in Children With Obesity as Young as 6 in Phase III Trial

Summary

Childhood obesity is a major driver of lifelong cardiometabolic risk, and treatment options for children under 12 are limited. The phase III STEP Young trial tested the GLP-1 drug semaglutide (Wegovy) in children ages 6 to 11 with obesity. At 68 weeks, average BMI fell 13.5% with semaglutide while it rose 2.7% with placebo. About 38% of children on the drug dropped below the obesity threshold, versus 2% on placebo. Results held at 104 weeks, though the gap narrowed slightly. In a DXA subgroup, fat mass percentage fell and lean tissue percentage rose. Height gain was lower with semaglutide, but bone age, bone density and puberty progression were similar between groups. The findings were presented at ObesityWeek and published in the New England Journal of Medicine.

Detailed Summary

Obesity that begins in childhood tends to persist into adulthood and raises the lifetime risk of type 2 diabetes, heart disease and early mortality. Roughly one in five U.S. children ages 6 to 11 has obesity, yet treatment is mostly limited to lifestyle programs, which typically reduce BMI only modestly (about 0.7 units) with uncertain durability. Semaglutide is approved for adolescents 12 and older, but not for younger children in the U.S.

The phase III STEP Young trial, run at 48 sites in nine countries from July 2023 to July 2026, tested weekly semaglutide against placebo in children ages 6 to 11 with obesity. At week 68, mean BMI dropped 13.5% with semaglutide and rose 2.7% with placebo, a between-group difference of 16.2 percentage points. By week 104, the changes were -9.4% versus +8.4%, a difference of 17.8 points. Thirty-eight percent of treated children fell below the 95th percentile threshold for obesity at week 68, compared with 2% on placebo; at week 104 the rates were 33% and 2%.

Safety around growth was a central concern. In a 50-child DXA subgroup, semaglutide produced a greater drop in fat mass percentage and a greater rise in lean soft-tissue percentage. Median height gain was lower with semaglutide (8.8 cm versus 12.1 cm at week 104), with slower height velocity. Bone age, bone mineral density and Tanner staging were similar. Because children with obesity often grow faster before puberty, researchers suggested the slower growth may reflect normalization of BMI.

Practically, the data suggest pharmacotherapy could become an option for younger children with obesity, potentially reducing long-term cardiometabolic risk. Any use would likely sit alongside lifestyle support and require monitoring of growth, body composition and pubertal development.

Caveats remain. This is a conference news report, the DXA subgroup was small, and the trial lasted two years. Long-term effects on adult height, body composition, weight regain after stopping and cardiovascular outcomes are unknown. Gastrointestinal side effects and the need for indefinite treatment also deserve scrutiny in the full publication.

Key Findings

  • At 68 weeks, BMI fell 13.5% with semaglutide versus a 2.7% rise with placebo in children ages 6 to 11.
  • 38% of treated children dropped below the obesity threshold at week 68, versus 2% on placebo.
  • At 104 weeks, BMI change was -9.4% with semaglutide versus +8.4% with placebo.
  • DXA subgroup showed greater fat mass loss and lean tissue percentage gain with semaglutide.
  • Height gain was lower on semaglutide, but bone age, bone density and puberty progression were similar.

Methodology

This is a news report from MedPage Today on a phase III, double-blind, placebo-controlled randomized trial published in the New England Journal of Medicine and presented at ObesityWeek. Source reporting is credible and quotes the investigators. Evidence is strong for BMI outcomes, weaker for growth and body composition subgroups.

Study Limitations

The article is a brief news summary and the text was truncated, so safety and side effect details are missing. The DXA subgroup was only 50 children, and long-term outcomes such as adult height and weight regain are unknown. Verify details in the NEJM publication.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: